RegulatoryOfficial

Denmark reports supply difficulty with Pfizer's Inlyta 7 mg axitinib tablets

🇩🇰 DKMA · Wed 04 Nov 2026

The Danish Medicines Agency expects Inlyta 7 mg film-coated tablets from Pfizer ApS to be constrained from early November to early December 2026, citing increased demand.

The Danish Medicines Agency (DKMA) has published a notice of current supply problems with Inlyta 7 mg film-coated tablets from Pfizer ApS. The notice is dated 4 November 2026.

Inlyta contains the active substance axitinib, ATC code L01EK01. DKMA gives the expected period of difficulty as the start of November to the start of December 2026.

The agency gives increased sales and demand as the cause. It does not state a manufacturing or quality problem, and the notice does not say how many patients or pharmacies may be affected.

DKMA says questions about the current status of supply should go to the company, Pfizer ApS. The notice sits in the agency's section on supply notifications for medicines. The text provided does not mention alternative products or specific mitigation measures.

What it means for your team

  • Supply-chain and market-access teams should note the expected November to early December 2026 window and check stock positions for Inlyta 7 mg in Denmark.
  • The stated cause is higher demand, not a quality defect, so no quality or recall action is indicated by the notice.
  • Teams needing up-to-date availability information should contact Pfizer ApS directly, as DKMA advises.
  • The notice lists no alternatives, so teams should check DKMA's supply notification pages for any further guidance.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Regulatory All →